KYTX

$7.30-$0.19 (-2.54%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$455.4M

61M shares

52-week range

$2.80 – $13.67

41% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-22.70

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$13M	+87.5%	$-2.87	$-3.07–$-2.67	—	5
2027	$18M	+40.3%	$-2.94	$-3.33–$-2.38	—	5
2028	$53M	+203.2%	$-2.39	$-2.87–$-1.69	—	3
2029	$175M	+228.3%	$-3.65	$-6.93–$-1.46	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-12	$-0.75	$-0.66	+12.0%
2026-03-26	$-0.84	$-0.80	+5.3%
2025-11-12	$-0.97	$-0.85	+12.4%
2025-08-12	$-1.00	$-0.97	+3.0%
2025-05-13	$-1.21	$-1.03	+14.9%
2025-03-27	$-0.87	$-0.88	-1.1%
2024-11-13	$-0.77	$-0.80	-3.9%
2024-08-12	$-0.70

DCF fair valuemodel estimate

Intrinsic value

$2.04

Price

$7.30

Implied downside

-72%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
KYTXKyverna Therapeutics, Inc.	$7.30	-2.54%	$444M	—
ALLOAllogene Therapeutics, Inc.	$1.88	-4.57%	$649M	—
AVIRAtea Pharmaceuticals, Inc.	$4.70	-0.84%	$376M	—
CABACabaletta Bio, Inc.	$2.68	-1.47%	$437M	—
CAPRCapricor Therapeutics, Inc.	$3.85	-8.11%

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

www.kyvernatx.com

Employees: 129
IPO / List date: Feb 8, 2024
HQ: EMERYVILLE, CA

Held by traders on TradeandTell

No one on the platform currently holds KYTX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	367,492	$3.2M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KYTX yet.

$KYTX chatter on StockTwits

The Legendary Mayor@BioRichBullish1d
@Jashem1980 That's a great question. I actually had a pretty extensive portfolio so I'll try to pare it down. If I were Buying 5 right now, I'd Buy: 1) $GUTS - High Risk/High Reward. Truly transformational opportunity if they resolve funding/listing (which I believe they do). 2) $RGNX - Great rebound opportunity, 3) $KYTX - Should get acquired; has people with stiff person syndrome walking normal again. They have patient videos. Insane. 4) $MIST - Rebound opportunity. Recent FDA approved and got crushed. Should be able to show revenues from new drug at upcoming earnings. 5) $ALT - Rebound opportunity? Despised this company and their previous management. True snakeoil salesman. Moved on to a hard nose CEO turning the company upside down. Recent dilution lowered SP, but brought in solid investors. Execution story at this point, with hopes of a partnership/Buyout pop. Hope these help. How about you? What are you long on or what's your favorites?
View on StockTwits ↗
Troy Jones@tmoney4572Bullish1d
$KYTX are we at $50 yet?
View on StockTwits ↗
Love Stock@lovestockstwits2d
$KYTX take it 0 and get it over with ..the most worthless stock at WS
View on StockTwits ↗
Matt@realmofloveBullish2d
$KYTX adding here
View on StockTwits ↗
Troy Jones@tmoney45722d
$KYTX
View on StockTwits ↗
blocktrade@blocktradeBullish2d
$KYTX sellers in this stock are just morons.
View on StockTwits ↗
YouKnow@abc123323d
$KYTX I have been watching this the last few days, since Clark resigned from the @CRVS BOD. Upon reviewing his other Board positions, I opened a position in OLMA on Friday and opened a position here today at 7.38. Good luck to all longs.
View on StockTwits ↗
The Legendary Mayor@BioRichBullish3d
$ALT Congrats on the AUD data. Today's news moves $ALT to my #2 holding behind $GUTS. Top 5 rounded out by $MIST, $KYTX and $ABVX
View on StockTwits ↗
Zack@ZackInvest0084d
$KYTX Pseudo BLA update?
View on StockTwits ↗
Harry@HarryScrotmmm4d
$KYTX anyone know how much this will cost kytx and if we will have to raise more capital ?
View on StockTwits ↗
Troy Jones@tmoney45724d
$KYTX add $ABEO
View on StockTwits ↗
jorge .miguel@focafoca994d
$KYTX inked a Clinical and Commercial Supply Agreement with ElevateBio for its miv-cel therapy.
View on StockTwits ↗
Kenny@kenny916554d
$KYTX Looks like it may finally jump at open
View on StockTwits ↗
Dutchie@Dutchholdem4d
$SLS $DRTS $KYTX $CABA on my watchlist today. Holding long positions in all
View on StockTwits ↗
bubba arnold@bubbarayjr5d
$KYTX Market Cap is less than $500M. After viewing the Before and After videos of patients with SPS, I expect the PPS to more than double after approval. It will go much higher (MC $5B+) is they can land a gMG approval. This article was written by the Senior Editor and well worth a read. All IMO https://www.biospace.com/business/how-kyverna-rode-car-ts-autoimmune-wave-to-the-fdas-door?utm_campaign=
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.